Crystagen

Identity and composition

Crystagen is a short peptide from the Khavinson family of bioregulators, studied in preclinical research as an immunomodulator associated with aging. It is marketed here in a presentation of 20 mg for laboratory use.

Product for research use.

As for its chemical identity, this compound is also known by the synonym Kristagen. No verified identity constants are available for publication: CAS number, molecular weight, molecular formula, and amino acid sequence could not be confirmed in reference sources (PubChem/DrugBank), so they are deliberately omitted. Supplier catalogs offer sequences that contradict one another, and none is backed by a peer-reviewed source, so no specific sequence is asserted here. Even the classification as a tri- or tetrapeptide remains unconfirmed.

Mechanism of action

Crystagen belongs to the class of short bioregulator peptides developed in the setting of the Institute of Bioregulation and Gerontology in Saint Petersburg (Khavinson). The proposed mechanism for this class is the regulation of gene expression in lymphoid tissue, although for Crystagen in particular the molecular details (DNA binding, signaling pathways) are not confirmed in open primary sources.

In the only study indexed in PubMed that explicitly names it, focused on the spleen during aging, Crystagen was observed to activates B-cell immunity, but does not induce cell renewal in the aged spleen, unlike other peptides of the same series (PMID 28976144).

These findings come from an experimental immunology/gerontology context and should not be extrapolated to effects in humans.

Pharmacokinetics

No pharmacokinetics (half-life, bioavailability) were located in verifiable sources. The "half-life" data in circulation come from supplier dosing guides and not from peer-reviewed primary literature, so no numerical value is reported here. Any such figure should be considered unconfirmed.

Scientific evidence

The available evidence on Crystagen is preliminary and limited. No registered clinical trials were found on ClinicalTrials.gov under this name, and the published information is limited to experimental gerontology and immunology studies in aging models (in vitro/animal context), focused on humoral immunity (B cells) of the spleen.

Within that framework, preliminary preclinical evidence suggests a role in the modulation of B-cell immunity, without promoting splenic cell renewal during aging (PMID 28976144). As this is a single indexed source, these results should be interpreted with caution and do not represent outcomes expected in humans.

Research applications

Product for research use.

• Ideal for: in vitro studies and animal models of immunology and gerontology; exploratory research lines on short peptide bioregulators and their role in humoral immunity (B cells) associated with aging; comparative work within the Khavinson peptide series.
• Not applicable for: clinical use, clinical, diagnostic or therapeutic use; self-administration; nor as a supplement. It is not approved as a drug.

Any extrapolation of the experimental findings to clinical use is speculative.

Research protocols

The consulted literature does not contain verifiable study doses for Crystagen. The only indexed source describes qualitative findings on B-cell immunity in the spleen (PMID 28976144), but no a dosing schedule supported by primary literature that could be reported here is available.

For reasons of responsibility, milligrams per study and numerical protocols are not indicated. The experimental design (dose, route and frequency) is left to the discretion of the researcher and the corresponding review of the literature.

Reconstitution

As a general laboratory handling guide for lyophilized peptides, reconstitution is usually done with bacteriostatic water (water with approximately 0.9% benzyl alcohol):

• Let the vial reach room temperature before opening it.
• Add the diluent, letting it run slowly down the inner wall of the vial, without directing the stream straight onto the powder.
• Do not shake; swirl gently until fully dissolved.
• The diluent volume is chosen according to the target concentration of the protocol.

This is a standard qualitative guide and not a specific validated parameter for Crystagen.

Stability and storage

As standard laboratory handling practice for peptides:

• Lyophilized (powder): store refrigerated or frozen, protected from light and humidity; the dry material is more stable during prolonged storage.
• Reconstituted (in solution): keep refrigerated and use within a short window; avoid repeated freeze and thaw cycles, which degrade peptides.

There are no specific stability data for Crystagen in verifiable sources, so these ranges are general handling guidelines.

Safety profile

No documented safety data were found for Crystagen in peer-reviewed literature or in regulatory sources, and no verifiable toxicological profile is available. Nor are there any formal contraindications on record.

The absence of published data no must be interpreted as an absence of risk. This material is handled as a research reagent: use appropriate personal protective equipment, follow good laboratory practices, and do not intend it for clinical use.

Comparative context

Crystagen is grouped with short peptides derived from or associated with Thymalin, along with Timogen y Vilon. In a comparative splenic study (PMID 28976144), the profiles described were as follows:

• Crystagen: activates B-cell immunity, but without promoting cellular renewal during aging.
• Thymogen: activates B cells and increases splenic proliferation.
• Vilon (and R-1): act on T-helper lymphocytes, reducing apoptosis.

These distinctions come from a single study and should be taken with caution; they do not constitute comparisons of clinical efficacy.

History and development

Crystagen falls within the line of short bioregulator peptides developed in the setting of the Institute of Bioregulation and Gerontology in St. Petersburg, associated with Khavinson's work on peptide regulators of the immune system and aging. It is investigated as a laboratory compound within that series, not as an approved drug. Its presence in the indexed literature is scarce: the main available reference places it among the short bioregulators evaluated in the spleen during aging (PMID 28976144).

FAQ

Scientific references (2)

Peer-reviewed literature on Crystagen, with its PubMed identifier when available:

• [Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process] (Chervyakova, et al. · Advances in Gerontology (Uspekhi Gerontologii) · 2014) PMID 28976144.
• Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats. (Voicekhovskaya MA, et al. · Bull Exp Biol Med · 2012) PMID 22803085.

Guides and articles about Crystagen

Lecturas del blog de EXOMA que la editorial asoció a este compuesto:

• Khavinson Bioregulators: Complete Guide to Cytomax Peptides

Other related research peptides

• Livagen
• Ovagen
• Pancragen
• Prostamax
• Testagen
• Thymalin
• Vesugen
• Vilon
• Bronchogen
• Cardiogen